BNT162b2 Protection against the Omicron Variant in Children and Adolescents

In this study evaluating BNT162b2, vaccine effectiveness against hospitalization for Covid-19 in the delta-predominant period among adolescents 12 to 18 years of age was more than 90%; during the omicron period, vaccine effectiveness was 40% against hospitalization and 79% against critical illness....

Full description

Saved in:
Bibliographic Details
Published inNew England Journal of Medicine Vol. 386; no. 20; pp. 1899 - 1909
Main Authors Price, Ashley M., Olson, Samantha M., Newhams, Margaret M., Halasa, Natasha B., Boom, Julie A., Sahni, Leila C., Pannaraj, Pia S., Irby, Katherine, Bline, Katherine E., Maddux, Aline B., Nofziger, Ryan A., Cameron, Melissa A., Walker, Tracie C., Schwartz, Stephanie P., Mack, Elizabeth H., Smallcomb, Laura, Schuster, Jennifer E., Hobbs, Charlotte V., Kamidani, Satoshi, Tarquinio, Keiko M., Bradford, Tamara T., Levy, Emily R., Chiotos, Kathleen, Bhumbra, Samina S., Cvijanovich, Natalie Z., Heidemann, Sabrina M., Cullimore, Melissa L., Gertz, Shira J., Coates, Bria M., Staat, Mary A., Zinter, Matt S., Kong, Michele, Chatani, Brandon M., Hume, Janet R., Typpo, Katri V., Maamari, Mia, Flori, Heidi R., Tenforde, Mark W., Zambrano, Laura D., Campbell, Angela P., Patel, Manish M., Randolph, Adrienne G.
Format Journal Article Web Resource
LanguageEnglish
Published United States Massachusetts Medical Society 19.05.2022
Subjects
Adolescent
Adolescent Medicine
Adolescents
Age
Age groups
Antigens
BNT162 Vaccine - therapeutic use
Case-Control Studies
Child
Child, Preschool
Children
Coronavirus
Coronaviruses
COVID-19
COVID-19 - prevention & control
COVID-19 vaccines
COVID-19 Vaccines - therapeutic use
Critical Illness - therapy
Electronic health records
Hospitalization
Hospitals
Humans
Illnesses
Immunization
Infectious Disease
Medical records
mRNA
mRNA Vaccines - therapeutic use
Original
Patients
Pediatrics
Pediatrics General
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Surveillance
Teenagers
Vaccine Efficacy
Vaccines
Vaccines, Synthetic - therapeutic use
Viral Infections
United States > US
Online AccessGet full text

Cover

More Information
Summary:In this study evaluating BNT162b2, vaccine effectiveness against hospitalization for Covid-19 in the delta-predominant period among adolescents 12 to 18 years of age was more than 90%; during the omicron period, vaccine effectiveness was 40% against hospitalization and 79% against critical illness. Vaccine effectiveness against hospitalization was 68% among children 5 to 11 years of age.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
A list of the Overcoming Covid-19 Investigators is provided in the Supplementary Appendix, available at NEJM.org.
Ms. Price, Ms. Olson, Dr. Patel, and Dr. Randolph contributed equally to this article.
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMoa2202826